Kurome Therapeutics closes $15 million Series A financing
Credit: CincyTech Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease modifying genes, today announced the closing of a $15 million Series A financing. The round was co-led by Medicxi and Affinity Asset Advisors with participation from founding investor CincyTech, and other existing seed investors. "We are excited to have the support of exceptional investors. This financing allows us to expand our R&D program to substantially de-risk compound selection as we ident...
Source: eurekalert.org